The mechanism of silicide

The mechanism of silicide formation at the apex of Si nanowire is two-stage silicidation. In the initial stage, as shown in Figure  9a, silicide grows in the radial direction, which is similar to the solid state reaction of metal film with a Si layer. The phase selection between metal and Si couples depends strongly on the atomic ratio

of Ni/Si. This dependence is observed not only in the thin film reactions [19] but also in the nanoparticle reactions [20]. In this study, the apex of Si nanowires covered with a considerable number of Ni atoms, which can be regarded as a system with a high Ni/Si atomic ratio, causing the formation of a metal-rich phase (Ni3Si2) at the Ni-coated part of Ni-silicide. Figure 9 Schematic illustrations of the mechanism of two-stage silicidation at the apex of Si nanowire. (a) A schematic illustration of the initial stage of silicidation.

(b) A schematic illustration of the second stage silicidation Selleck Milciclib in the Si nanowire with small diameter. (c) A schematic illustration of the second stage silicidation in the Si nanowire with large diameter. In the second stage, the Ni silicide axially intruded into the Si nanowire from the Ni-coated part located at the front of the nanowire. Such penetration of Ni silicide involves different thermally activated processes, such as the volume, surface, and interface diffusions of Ni. In this study, the phase selection depended on the diameter of the Si nanowires, such that NiSi2 and NiSi were observed in nanowires Farnesyltransferase selleck screening library with large diameters and small diameters, respectively.

The reasons for this phenomenon are discussed as follows. First, the location of silicide nucleation in the Si nanowires in the axial Citarinostat order direction is discussed. Wu et al. [11] studied the formation of Ni silicide in the Si nanowires through point and line contact reaction. By the point contact reaction between Ni nanodots and a Si nanowire, the nucleation and growth of NiSi grains start at the middle of the point contacts. By the line contact reaction between PS nanosphere-mediated Ni nanopatterns and a Si nanowire, silicide growth starts in the contact area. Wu et al. concluded that the mechanism of silicide growth in Si nanowires is based on the basis of flux divergence. Lu et al. [21] obtained the similar results for the formation of Pt silicide in the Si nanowires. They also performed molecular dynamic simulations to support the experimental results: a low atom flux of Pt caused the dissolution and distribution of Pt in the Si nanowire. Then, the nucleation of a silicide can occur between the two contacts where the Pt atoms dissolve, and the most probable site of nucleation is the middle because of the buildup of concentration that occurs in the middle. Second, the position of nucleation of silicide in Si nanowires in the radial direction is discussed. Chou et al. studied the growth of NiSi [22] and NiSi2[23] in Si nanowires by in situ high-resolution TEM.

Conjugations were performed using both the Salmonella isolates an

Conjugations were performed using both the Salmonella isolates and their respective E. coli transformants. Ceftriaxone (2 μg/ml) and chloramphenicol (15 μg/ml) were used to select for the transfer of CMY+ and CMY- plasmids, respectively. Transfer efficiencies were calculated as the number of transconjugants per donor. Acknowledgements This work was partially funded by research grants from CONACyT/Mexico

(No.82383 and No. 60227) and DGAPA/UNAM (No. 216310 and 205107) to EC and Ricardo Oropeza; by a Ph.D. fellowship from CONACyT (No. 214945) to MW; and by a postdoctoral fellowship to CS from CONACyT (No. 60796). We are grateful to all the people that kindly supplied reference strains: E. coli V157 was provided by Francis L. Macrina, E. coli AR060302 was provided by Douglas R. Call, Newport SN11 was provided by Toni L. Poole and Dayna Harhay, and E. coli E2348/69 was provided by Alejandro Huerta. selleck screening library We appreciate the technical assistance of Elvira Villa; the administrative support of Amapola Blanco and

Rosalva González; and the primer synthesis and sequencing service given by Eugenio López, Santiago Becerra, Paul Gaytán and Jorge Yañez at the Instituto de Biotecnología, UNAM. Rafael Díaz (CCG, UNAM) and Cindy Dierikx (Central Veterinary Institute, the Netherlands) helped us with the S1 PFGE protocol. Electronic supplementary material Additional file 1: Table S1. Primers used in this study. (DOC 113 KB) Additional file 2: Table S2. learn more Isolates sequenced and GenBank accession numbers. (DOC 36 KB) References 1. Levin BR, Bergstrom CT: Bacteria are different: observations, interpretations, speculations, and Compound C opinions about the DOK2 mechanisms of adaptive evolution in prokaryotes. Proc Natl Acad Sci USA 2000, 97: 6981–6985.PubMedCrossRef 2. Heuer H, Abdo Z, Smalla K: Patchy distribution of flexible genetic elements in bacterial populations mediates robustness to environmental uncertainty. FEMS Microbiol Ecol 2008,

65: 361–371.PubMedCrossRef 3. Souza V, Eguiarte LE: Bacteria gone native vs. bacteria gone awry?: plasmidic transfer and bacterial evolution. Proc Natl Acad Sci USA 1997, 94: 5501–5503.PubMedCrossRef 4. Couturier M, Bex F, Bergquist P, Maas WK: Identification and classification of bacterial plasmids. Microbiol Rev 1988, 52: 375–395.PubMed 5. Fricke WF, Welch TJ, McDermott PF, Mammel MK, LeClerc JE, White DG, Cebula TA, Ravel J: Comparative genomics of the IncA/C multidrug resistance plasmid family. J Bacteriol 2009, 191: 4750–4757.PubMedCrossRef 6. Call DR, Singer RS, Meng D, Broschat SL, Orfe LH, Anderson JM, Herndon DR, Kappmeyer LS, Daniels JB, Besser TE: blaCMY-2-positive IncA/C plasmids from Escherichia coli and Salmonella enterica are a distinct component of a larger lineage of plasmids. Antimicrob Agents Chemother 2010, 54: 590–596.PubMedCrossRef 7. McIntosh D, Cunningham M, Ji B, Fekete FA, Parry EM, Clark SE, Zalinger ZB, Gilg IC, Danner GR, Johnson KA, et al.

All of these alterations will finally lead to angiogenesis, matri

All of these alterations will finally lead to angiogenesis, matrix degradation and metastasis

in cancer. Cancer cells adapt to hypoxia for survival [26]. It is reported that BLyS suppresses the progression of several kinds of Fer-1 tumors and plays an important role in the development of immune system diseases [27]. However, our results showed an enhanced migratory in response to BLyS. Several reports support the critical roles of Akt and p38 MAPK in cancer cell survival, migration, apoptosis and anti-apoptosis [28, 29]. Previous research indicated that BLyS led to rapid phosphorylations of Akt in B cells [30]. Our studies suggested that phosphorylations of Akt were essential for BLyS-enhanced cell migration in vitro. Conclusion In conclusion, the results found that BLyS caused the enhanced migration of human breast cancer cells, while BLyS was up-regulated by hypoxia. However, further studies are required to confirm the mechanisms of BLyS action and reveal the relationship between inflammation and breast cancer progression. Acknowledgements This

work was supported by the Standardized Platform Construction and Scientific Application in New Technologies for New Drug Screening (No.2009ZX09302-002), the Study of Saponin Monomer of Dwarf Lilyturf Tuber (DT-13): A new Natural Anti-metastatic Drug Candidate (No.2009ZX09103-308) and the Research on Anti-tumor metastasis effectof YS-1 (No.81071841) TPCA-1 clinical trial References 1. Woodland RT, Schmidt MR, Thompson CB: BLyS and B cell homeostasis. Semin Immunol 2006, 18:318–326.PubMedCrossRef 2. KU55933 cell line Tangye SG, Bryant VL, Cuss AK, Good KL: BAFF, APRIL and human B cell disorders. Semin Immunol 2006, 18:305–317.PubMedCrossRef 3. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel K, Gross JA, Greipp PR, Jelinek DF: Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004, 103:689–694.PubMedCrossRef 4. Parameswaran R, David HB, Sharabi A, Zinger H, Mozes E: B-cell activating

factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus. Clin this website Immunol 2009, 131:223–232.PubMedCrossRef 5. Kalled SL: Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 2006, 18:290–296.PubMedCrossRef 6. Pelekanou V, Kampa M, Kafousi M, Darivianaki K, Sanidas E, Tsiftsis DD, Stathopoulos EN, Tsapis A, Castanas E: Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas. BMC Cancer 2008, 8:76.PubMedCrossRef 7. Rosmorduc O, Housset C: Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010, 30:258–270.PubMedCrossRef 8.

With the increase of the magnetic field, the current amplitude in

With the increase of the magnetic field, the current amplitude in [110] crystallographic direction increased faster than that in [1 0] crystallographic direction, despite the magnetic field-independent background current in Figure 7b. Figure 7 The magneto-photocurrents J q in (a) [110] and (b) [1 0] crystallographic directions. Selleckchem BAY 11-7082 The red parabolic-shape lines are fitting curves of the

currents. Conclusions In summary, we have researched magneto-photocurrents in the InAs/GaSb superlattice when an in-plane and tilted magnetic field were applied respectively. The magneto-photocurrents in both conditions are insensitive to the polarization state of the incident light. A theoretical model involving anisotropic photo-excited carriers density is utilized to explain the in-plane magnetic field-induced MPE. Compared to the direct electron-photon interaction, the asymmetric electron-phonon interaction which contributes to the magneto-photocurrent may be more sensitive to the radiation polarization state. The quadratic magnetic field dependence of the magneto-photocurrents can be well illustrated by an additional Hall effect model. Acknowledgements The work was supported by the 973 Program (2012CB921304 and 2013CB632805) and the National Natural Science Foundation of China (Nos. 60990313, 61176014, 61307116 and 61290303). References 1. žutić I, Fabian J, Das Sarma S: Spintronics: fundamentals and applications.

Rev Mod Phys 2004, 76:323–410. doi:10.1103/RevModPhys.76.323CrossRef 2. Wolf SA, Awschalom DD, Buhrman

RA, Daughton JM, von Molnár S, Roukes ML, Chtchelkanova AY, Treger DM: Spintronics: a spin-based electronics vision for the future. Science GW3965 2001,294(5546):1488–1495. doi:10.1126/science.1065389CrossRef 3. Ganichev SD, Prettl W: Spin photocurrents in quantum wells. J Phys: Condens Matter 2003,15(20):935. 4. Bel’kov VV, Ganichev SD: Magneto-gyrotropic effects in semiconductor quantum wells. Semiconductor Sci Technol 2008,23(11):114003.CrossRef 5. Dai J, Lu H-Z, Yang CL, Shen S-Q, Zhang F-C, Cui X: Magnetoelectric photocurrent generated by direct interband transitions in N-acetylglucosamine-1-phosphate transferase InGaAs/InAlAs two-dimensional electron gas. Phys Rev Lett 2010, 104:246601. doi:10.1103/PhysRevLett.104.246601CrossRef 6. Lechner V, Golub LE, Lomakina F, Bel’kov VV, Olbrich P, Stachel S, Caspers I, Griesbeck M, Kugler M, Hirmer MJ, Korn T, Schüller C, Schuh D, Wegscheider W, Ganichev SD: Spin and orbital mechanisms of the magnetogyrotropic photogalvanic effects in GaAs/Al x Ga 1− x As quantum well structures. Phys Rev B 2011, 83:155313. doi:10.1103/PhysRevB.83.155313CrossRef 7. Drexler C, Tarasenko SA, Olbrich P, Karch J, Hirmer M, Müller F, PF-3084014 Gmitra M, Fabian J, Yakimova R, Lara-Avila S, Kubatkin S, Wang M, Vajtai R, Ajayan M, Kono J, Ganichev SD: Magnetic quantum ratchet effect in graphene. Nat Nano 2013,8(2):104–107.CrossRef 8. Ting DZ-Y, Cartoixà X: Resonant interband tunneling spin filter. Appl Phys Lett 2002,81(22):doi:10.1063/1.1524700.CrossRef 9.

Bladder consensus conference committee Am J Surg Pathol 1998, 22

Bladder consensus conference committee. Am J Surg Pathol 1998, 22:1435–1448.PubMedCrossRef 3. Lee R, Droller MJ: The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000, 27:1–13. viiPubMedCrossRef 4. Said N, Theodorescu D: Pathways of metastasis suppression in bladder cancer. Cancer

Metastasis Rev 2009, 28:327–333.PubMedCrossRef 5. Villares GJ, Zigler M, Blehm K, Bogdan C, McConkey D, et al.: Targeting EGFR in bladder cancer. World J Urol 2007, 25:573–579.PubMedCrossRef 6. Neal DE, Mellon K: Epidermal growth factor receptor and bladder cancer: a review. Urol Int 1992, 48:365–371.PubMedCrossRef 7. Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, et al.: Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 2008, 179:353–358.PubMedCentralPubMedCrossRef 8. Witters L, Kumar R, Mandal M, Bennett CF, Miraglia Selleck Fosbretabulin L, et selleck chemicals llc al.: Antisense oligonucleotides to the epidermal growth factor receptor. Breast Cancer Res Treat 1999, 53:41–50.PubMedCrossRef 9. Bhuvaneswari R, Gan YY, Soo KC, Olivo M: Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer 2009, 8:94.PubMedCentralPubMedCrossRef 10. Nilsson J, Vallbo C, Guo D,

Golovleva I, Hallberg B, et al.: Pevonedistat mw Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun 2001, 284:1155–1161.PubMedCrossRef 11. Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, et al.: Characterization and tissue-specific expression of human LRIG2.

Gene 2004, 332:35–43.PubMedCrossRef 12. Guo D, Holmlund C, Henriksson R, Hedman H: The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics 2004, 84:157–165.PubMedCrossRef 13. Gur G, Rubin C, Katz M, Amit I, Citri A, et al.: LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 2004, 23:3270–3281.PubMedCrossRef 14. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, et al.: The leucine-rich repeat Y-27632 2HCl protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 2004, 279:47050–47056.PubMedCrossRef 15. Yang WM, Yan ZJ, Ye ZQ, Guo DS: LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87. BJU Int 2006, 98:898–902.PubMedCrossRef 16. Li F, Ye ZQ, Guo DS, Yang WM: Suppression of bladder cancer cell tumorigenicity in an athymic mouse model by adenoviral vector-mediated transfer of LRIG1. Oncol Rep 2011, 26:439–446.PubMed 17. Goel S, Hidalgo M, Perez-Soler R: EGFR inhibitor-mediated apoptosis in solid tumors. J Exp Ther Oncol 2007, 6:305–320.PubMed 18. Wang Z, Sengupta R, Banerjee S, Li Y, Zhang Y, et al.

Zhongguo Fei

Ai Za Zhi 2008, 11:489–494 PubMed 24 Rorke

Zhongguo Fei

Ai Za Zhi 2008, 11:489–494.PubMed 24. Rorke S, Murphy S, Khalifa M, Chernenko G, Tang SC: Prognostic significance of BAG-1 expression in nonsmall cell lung cancer. Int J Cancer 2001, 95:317–322.PubMedCrossRef 25. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J: BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004, 13:2443–2449.PubMedCrossRef 26. Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GKF, Mullan PB, Johnston PG, Wilson RH, Harkin DP: BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy. Clin Cancer Res 2007, 13:7413–7420.PubMedCrossRef PX-478 27. Bartolucci R, Wei J, Sanchez JJ, Perez-Roca L, Chaib I, Puma F, Farabi R, Mendez

P, Roila F, Okamoto T, et al.: XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer 2009, 10:47–52.PubMedCrossRef 28. Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, Chaib I, Provencio M, Domine M, Sala MA, Jimenez U, et al.: Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009, 4:e5133.PubMedCrossRef 29. Kim D, Jung W, Koo JS: The expression of ERCC1, Captisol mouse RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. J Korean Med Sci 2011, 26:352–359.PubMedCrossRef 30. Su C, Zhou S, Zhang L, Ren S, Xu J, Zhang J, Lv M, Zhou C: ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced

non-small cell lung cancer. Med Oncol 2010, 28:1411–1417.PubMedCrossRef 31. Pitterle DM, Kim YC, Jolicoeur EM, Cao Y, O’Briant KC, Bepler G: Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm H 89 clinical trial Genome 1999, 10:916–922.PubMedCrossRef Rebamipide 32. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA: An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines. Cancer Res 2004, 64:3761–3766.PubMedCrossRef 33. Liu B, Staren ED, Iwamura T, Appert HE, Howard JM: Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J Surg Res 2001, 99:179–186.PubMedCrossRef 34. Gan PP, Pasquier E, Kavallaris M: Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007, 67:9356–9363.PubMedCrossRef 35. Koh Y, Jang B, Han SW, Kim TM, Oh DY, Lee SH, Kang CH, Kim DW, Im SA, Chung DH, et al.: Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol 2010, 5:320–325.PubMedCrossRef Competing interests The authors declare that they have no competing interests.

At time 0, 5 and 15 min, 300 μl of the culture was withdrawn and

At time 0, 5 and 15 min, 300 μl of the culture was withdrawn and immediately filtered on a 0.2

μm 96-well filter plate (Pall, East Hills, NY). The CBL-0137 purchase number of free phages in each sample was then determined by plating. Six replicates were performed for each phage strain. An exponential function of y = be -at , where a and b are the parameters to be estimated, and t the time, was used to fit the data from individual experiments. The adsorption rate was obtained by dividing each of the estimated parameter a with its corresponding cell concentration. For more detail on how the adsorption rates were calculated, please see Additional file 3. Determination of plaque size For each phage strain, images of four to five plates with phage plaques were taken with Qcount (Spiral Biotech, Inc.; Norwood, MA) and then analyzed using

the ImageJ software (NIH). To convert the pixel count to surface area, we arbitrarily generated a computer printout with a known surface area and used it as the size standard. In this study, we found that 1 pixel = 0.01588 mm2. Besides the phage traits, many other factors may also influence the plaque size. Several precautions were taken to minimize potential unintended effects. For example, to minimize plaque variation due to plating conditions [12], the plating conditions were standardized and only freshly prepared plates were used (see above). To reduce variation due learn more to the timing of the formation of the initial attachments of phage particles, adequate amount of pre-adsorption time and high host concentrations (see above) were used to synchronize the timing of the formation of the initial infection centers before plating. This practice is especially critical for phages with low adsorption rates. To reduce the incidence of fusion of two nearby plaques, thus being measured as one large plaque, the Amino acid number of phages on each plate was kept below 100. However, other factors, such as the edge effect

(plaques on the edge of the plate were usually smaller), were unable to be controlled. Therefore, to further minimize potential skewing effects, plaque size distributions obtained from the four to five replicated plates were pooled, and the mode, rather than the mean, was used as the descriptive measure of these distributions. The determination of plaque size was performed nine times independently. Determination of plaque productivity In order to estimate phage numbers in plaques (productivity), three random plaques from each of the four plates (used to estimate plaque size – see above) were obtained by taking agar plugs containing the plaques [17]. The 12 plaques were pooled STAT inhibitor together and then homogenized in 6 mL TB medium using a glass homogenizer with a Teflon plunger [17]. The homogenate was centrifuged for 10 min at 3000 × g (Eppendorf centrifuge 5702) at room temperature and the supernatant was then plated in triplicates at appropriate dilutions on a lawn of E.

Microbiology 1998,144(Pt 2):425–432 PubMedCrossRef 17 Srikantha

Microbiology 1998,144(Pt 2):425–432.PubMedCrossRef 17. Srikantha T, Tsai L, Daniels K, Enger L, Highley K, Soll DR: The two-component hybrid kinase regulator CaNIK1 of Candida albicans. Microbiology 1998,144(Pt 10):2715–2729.PubMedCrossRef 18. Alex LA, Korch C, Selitrennikoff CP, Simon MI: COS1, a two-component histidine kinase that is involved in hyphal development in the opportunistic pathogen Candida albicans. Proc Natl

Acad Sci USA 1998, 95:7069–7073.PubMedCrossRef 19. Ochiai N, Fujimura M, Motoyama T, Ichiishi A, Usami R, Horikoshi K, Yamaguchi I: Characterization of mutations in the two-component histidine kinase gene that confer fludioxonil resistance and osmotic sensitivity in the os-1 mutants Pexidartinib purchase of Neurospora crassa. Pest Manag Sci 2001, 57:437–442.PubMedCrossRef 20. Ochiai N, Fujimura M, Oshima M, Motoyama T, Ichiishi A, Yamada-Okabe H, Yamaguchi I: Effects of iprodione and fludioxonil on glycerol synthesis and hyphal development in Candida albicans. Biosci Biotechnol Biochem 2002, 66:2209–2215.PubMedCrossRef 21. Motoyama T, Kadokura K, Ohira T, Ichiishi A, Fujimura M, Yamaguchi I, Kudo T: A two-component histidine kinase of the

rice blast fungus is involved in osmotic stress response and fungicide action. Fungal Genet Biol 2005, 42:200–212.PubMedCrossRef 22. Knauth P, Reichenbach H: On the mechanism of action of the myxobacterial fungicide ambruticin. J Antibiot (Tokyo) 2000, 53:1182–1190.CrossRef 23. Furukawa K, Randhawa A, Kaur H, Mondal AK, Hohmann S: Fungal fludioxonil sensitivity is FK228 chemical structure diminished by a constitutively Thiazovivin active form of the group III histidine kinase. FEBS Lett 2012, 586:2417–2422.PubMedCrossRef 24. Yoshimi A, Kojima K, Takano Y, Tanaka C: Group III histidine kinase is a positive regulator of Hog1-type mitogen-activated protein kinase in filamentous fungi. Eukaryot Cell 2005, 4:1820–1828.PubMedCrossRef 25. Buschart A, Gremmer K, El-Mowafy

else M, van den Heuvel J, Mueller PP, Bilitewski U: A novel functional assay for fungal histidine kinases group III reveals the role of HAMP domains for fungicide sensitivity. J Biotechnol 2012, 157:268–277.PubMedCrossRef 26. Motoyama T, Ohira T, Kadokura K, Ichiishi A, Fujimura M, Yamaguchi I, Kudo T: An Os-1 family histidine kinase from a filamentous fungus confers fungicide-sensitivity to yeast. Curr Genet 2005, 47:298–306.PubMedCrossRef 27. Vetcher L, Menzella HG, Kudo T, Motoyama T, Katz L: The antifungal polyketide ambruticin targets the HOG pathway. Antimicrob Agents Chemother 2007, 51:3734–3736.PubMedCrossRef 28. Dongo A, Bataille-Simoneau N, Campion C, Guillemette T, Hamon B, Iacomi-Vasilescu B, Katz L, Simoneau P: The group III two-component histidine kinase of filamentous fungi is involved in the fungicidal activity of the bacterial polyketide ambruticin. Appl Environ Microbiol 2009, 75:127–134.PubMedCrossRef 29.

Oncogene 2005,24(46):6861–6869 PubMedCrossRef 12 Strumberg D: Pr

Oncogene 2005,24(46):6861–6869.PubMedCrossRef 12. Strumberg D: Preclinical and clinical development of the oral multikinase inhibitor sorafenib in EPZ015938 mouse cancer treatment. Drugs Today (Barc) 2005,41(12):773–784.CrossRef 13. Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, Lathia C, Petrenciuc O, Moore MJ: Phase I trial of sorafenib

and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006,12(1):144–151.PubMedCrossRef 14. Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, Nattam S, Agamah E, Stadler WM, Vokes EE: Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs 2012,30(1):382–386.PubMedCrossRef 15. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA: A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic

pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs 2008,26(5):463–471.PubMedCrossRef selleck products 16. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O’Reilly E, Wozniak TF: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010,28(22):3617–3622.PubMedCrossRef 17. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with

advanced pancreatic cancer. Br J Cancer 2002,87(2):161–167.PubMedCrossRef 18. Dragovich T, Burris H 3rd, Loehrer P, Von Hoff DD, Chow S, Stratton S, Green S, Obregon Y, Alvarez I, Gordon M: Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol 2008,31(2):157–162.PubMedCrossRef 19. Assifi MM, Hines OJ: Anti-angiogenic agents in pancreatic cancer: a review. Anticancer Benzatropine Agents Med Chem 2011,11(5):464–469.PubMedCrossRef 20. Longo R, Cacciamani F, Naso G, Gasparini G: Pancreatic cancer: from molecular signature to target therapy. Crit Rev Oncol Hematol 2008,68(3):197–211.PubMedCrossRef 21. buy Salubrinal Schwarz RE, Awasthi N, Konduri S, Cafasso D, Schwarz MA: EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer. Ann Surg Oncol 2010,17(5):1442–1452.PubMedCrossRef 22. Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE: Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. PLoS One 2012,7(6):e38477.PubMedCrossRef 23.

Hymenomyc Suec (Upsaliae) 2(2): 312 (1863): Icon t 167, f 3

Hymenomyc. Suec. (Upsaliae) 2(2): 312 (1863): Icon. t. 167, f. 3. Epitype selected by Dentinger, Ainsworth, Griffith and Cannon: Sweden, coll. K. Bergelin, 8 Oct. 2011, LD 1617064 Genus Gloioxanthomyces Lodge, Vizzini, Ercole & Boertm., [or a new subgenus or section for

Hygrocybe nitida and H. vitellina] Table 2 Taxonomy of Hygrophoraceae, subfamilies Hygrophoroideae and Lichenomphalioideae and the cuphophylloid grade. Taxa are organized in this table hierarchically and by the branching order in the 4-gene backbone and Supermatix analyses (Figs. 1 and 2) and the Hygrophorus ITS analysis (Online Resource 9) Subfamily Hygrophoroideae E. Larsson, Lodge, Vizzini, Norvell & Redhead, subf. nov., type genus Hygrophorus Fr., Fl. Scan.: 339 (1836) [1835] Tribe Chrysomphalineae Romagn., Bull. Soc., Mycol. Fr. 112(2): 135 (1996), emend. Lodge, Padamsee, Norvell, Vizzini & Redhead, Transferred from Cantharellaceae NSC 683864 mouse tribe Chrysomphalineae Romagn., Doc. Mycol. 25(98–100): 135 (1996), type genus Chyrsomphalina

Clémençon, Z. Mykol. 48(2): 202 (1982) [≡ Cantharellaceae tribe “Paracantharelleae” Romagn., Doc. Mycol. Fr. 25(98–100): 418 (1995) nom. invalid, Art. 18.1] Genus Chrysomphalina Clémençon, selleck Z. Mykol. 48(2): 202 (1982), type GS-9973 research buy species Chrysomphalina chrysophylla (Fr. : Fr.) Clémençon, Z. Mykol. 48(2): 203 (1982), ≡ Agaricus chrysophyllus Fr. : Fr., Syst. mycol. (Lundae) 1: 167 (1821) Genus Haasiella Kotl. & Pouzar, Ceská Mykol. 20(3): 135 (1966), type species Haasiella venustissima (Fr.) Kotl. & Pouzar ex Chiaffi & Surault (1996), ≡ Agaricus venustissimus Fr., Öfvers Kongl. Svensk Vet.-Akad, Förh. 18: 21 (1861) Genus Aeruginospora Höhn. Sber. Akad. Wiss. Wein, Math.-naturw. Kla., Abt. 1 117: 1012 (1908), type species Aeruginospora singularis Höhn.,

Sber. Akad. Wiss. Wien, Math.-naturw. Kl., Abt. 1 117: 1012 (1908) Tribe Hygrophoreae P. Henn., in A. Engler & E.A. Prantl, Nat. Pflanzenfam. 1: 209 (1898), emend. Kühner, Bull. mens. Soc. linn. Lyon 48: 617 (1979), type genus Hygrophorus Fr., Fl. Scan.: 339 (1836) [1835] Genus Hygrophorus Fr., Fl. Scan.: 339. (1836) [1835], type species Hygrophorus eburneus (Bull. : Fr.) Fr., Epicr. syst. mycol. C59 solubility dmso (Upsaliae): 321 (1836) [1836–1838], ≡ Agaricus eburneus Bull., Herb. Fr. 3: tab. 118, tab. 551, fig. 2 (1783) Subgenus Hygrophorus [autonym] (1849), Emended here by E. Larss., type species Hygrophorus eburneus (Bull.) Fr., Epicr. syst. mycol. (Upsaliae): 321 (1836) [1836–1838], ≡ Agaricus eburneus Bull., Herb. Fr. 3: tab. 118, tab. 551, fig. 2 (1783) Section Hygrophorus [autonym] type species Hygrophorus eburneus (Bull.) Fr., Epicr. syst. mycol. (Upsaliae): 321 (1836) [1836–1838], ≡ Agaricus eburneus Bull., Herb. Fr. 3: tab. 118, tab. 551, fig. 2 (1783) Subsection Hygrophorus [autonym] type species Hygrophorus eburneus (Bull.) Fr., Epicr. syst. mycol. (Upsaliae): 321 (1836) [1836–1838], ≡ Agaricus eburneus Bull., Herb. Fr. 3: tab. 118, tab. 551, fig.